ArticleScientific reports2025

Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases.

Le Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.